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1. Introduction 
Considerable attention has been recently focused on 
the physiological significance of steroid hormone conju- 
gates. Usually the conjugated steroids are determined 
indirectly after hydrolysis by enzymatic and/or 
chemical means. Such procedures have inevitable 
disadvantages of lack of reliability due to incomplete 
hydrolysis and formation of artifacts, and in loss of 
information about the conjugate forms. Consequently 
several investigators have attempted to prepare anti- 
steroid glucuronide sera for use in radioimmunoassays 
[l-5]. However, antisera so far obtained are not 
satisfactory in respect of specificity. We have under- 
taken the development of a radioimmunoassay method 
specific for oestrogen glucuronides without prior 
hydrolysis. In this communication we report the 
synthesis of oestradiol 17-glucuronide-bovine s rum 
albumin (BSA) conjugate in which the hapten is linked 
to protein through the C-2 position and characterisation 
of antiserum raised against i . 
2. Materials and methods 
2.1. Reagents 
[6,7-3H] Oestradiol 17.glucuronide (spec. act. 45.9 
Ci/mmol) was supplied by New England Nuclear, 
Boston, USA. Methyl (3.hydroxy 1,3,5(10)-oestratrien- 
17~yl-2,3,4-tri-0-acetyl-PD-glucopyranoside)uronate 
(oestradiol 17-glucuronide acetate-methyl ester) and 
other conjugated steroids were prepared in these 
laboratories. All other steroids were kindly donated 
from Teikoku Hormone Co., Tokyo, Japan. General 
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reagents were purchased from Nakarai Chemicals, Ltd, 
Kyoto, Japan and all solvents were redistilled prior to 
use. 
2.2. Preparation of antigen 
To a solution of oestradiol 17.glucuronide acetate- 
methyl ester (I) (400 mg) in acetic acid (10 ml)-chloro- 
form (5 ml) was added cont. HN03 (0.07 ml) dropwise 
and stirred at room temperature for 20 min. The 
resulting solution was poured into ice-water, neutralised 
and extracted with ethyl acetate. The organic phase 
was washed with water, dried (Na2S04) and evaporated. 
An oily residue was chromatographed onsilica gel. 
Elution with benzene-ether (95:5) and recrystalli- 
sation of the eluate from methanol gave 2-nitro- 
oestradiol 17-glucuronide acetate-methyl ester (II) 
(159 mg) as pale-yellow needles, m.p. 201-204”C, 
[(Y]E t 23.6”C (c = 0.89., CHC13). 
Nmr (CDC13)8 : 
0.78 (3H, S, l8-CH3) 
2.00 (6H, s, -COCH3) 
3.74 (3H, s, -COOCH3) 
4.60 (1 H, d, J = 7 Hz, pyranose+-H) 
4.85-5.35 (4H, m, pyranose-CH-OAc) 
6.82 (lH, s, 4-I-I) 
7.95 (lH, s, 1-I-Q 
To a solution of II (150 mg) in methanol (10 ml) 
was added 1 N NaOH (1.4 ml) and the mixture allowed 
to stand at 4°C for 3 days. The resulting precipitate 
was collected by filtration and recrystallised from 
methanol to give the sodium salt of 2-nitro-oestradiol 
17-glucuronide (III) (50 mg) as red plates, m.p. 
> 3OO”c, [a] “D” -7.9”C (c = 0.81, H,O). 
Nmr (DzO)6 :
1.19 (3H, s, 18-CH,) 
3.90-4.50 (4H, m, pyranose-CH-OH) 
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4.93 (1 H, d, J = 7 Hz, pyranose-G-H) 
6.92 (1 H, s, 4-H) 
8.12 (lH, s, 1-H). 
To a solution of III (80 mg) in 0.1 N NaOH (5 ml) 
was added NazSs04 (240 mg) and the mixture stirred 
at room temperature for 1 h. The resulting solution 
was passed through a column of Amberlite XAD-2 
resin. After thoroughly washing the resin with distilled 
water the glucuronide was eluted with methanol. The 
eluate was further purified by chromatography on a 
Sephadex G-25 column. The desired fractions were 
collected and lyophilised to give 2-amino-oestradiol 
17glucuronide (IV) (65 mg). 
Nmr (pyridine-d,)6 : 
1.15 (3H, s, 18-CHa) 
3.9 l-4.60 (4H, m, pyranose-CH-OH) 
4.90 (lH, d, J = 7 Hz, pyranose-Cr-H) 
6.92 (lH, s, 4-H) 
8.02 (lH, s, 1-H) 
The derivatised steroid (IV) (50 mg) was coupled 
to BSA (110 mg) by condensation with glutaraldehyde 
[6] followed by reduction with NaB&. The reaction 
mixture was processed in the usual manner to provide 
a steroid-BSA conjugate (V) (130 mg) as a fluffy 
powder. The molar steroid:protein ratio of the conju- 
gate was determined spectrometrically (at 295 nm) 
to be 15. 
2.3. Immunisation and characteriwtion of antiserum 
A domestic strain male albino rabbit was immunised 
with the conjugate and antiserum raised against it was 
characterised as previously reported [7]. 
3. Results 
Five months after initial injection serum from the 
immunised rabbit showed a remarkably increased 
I: R=H 
II : R=NOz 
Fig.1 We have used 2-amino-oestradiol 17glucuronide, 
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Table 1 
Per cent cross-reaction of anti-oestradiol lllglucuronide 
antiserum with selected steroids 
Steroid 
Oestradiol 17-ducuronide 
Testosterone 1 ‘I-glucuronide 
Oestrone glucuronide 
Oestradiol3-glucuronide 
16-Epioestriol3ghrcuronide 
Oestriol3glucuronide 
Oestriol 16gJucuronide 
Oestriol 17ghrcuronide 
2-Hydroxyoestradiol2-glucuronide 
Androsterone ghrcuronide 
Pregnanediol 3glucuronide 
Oestradiol 17-sulphate 
Oestriol3-sulphate 
2-Hydroxyoestradiol3-sulphate 
Dehydroepiandrosterone sulphate 
Oestrone 
Oestradiol 
Oestriol 
16-Epioestriol 
2-Hydroxyoestradiol 
2-Methoxyoestrone 
Testosterone 
Progesterone 
Cortisol 
Cross-reaction (%) 
100 
2.94 
0.10 
0.10 
0.19 
< 0.001 
< 0.001 
0.06 
< 0.001 
< 0.001 
< 0.001 
< 0.001 
< 0.001 
< 0.001 
< 0.001 
< 0.001 
< 0.001 
< 0.001 
< 0.001 
< 0.001 
< 0.001 
< 0.001 
< 0.001 
< 0.001 
binding activity to oestradiol 17-glucuronide. The 
association constant (K,) was determined to be 
2.58 X 1 O9 M-’ by a Scatchard plot [8 3. A standard 
curve was constructed with a 1:20 000 dilution of the 
rabbit serum using tritiated oestradiol 17-glucuronide 
as labelled antigen. The cross-reactivity of anti-oestra- 
diol 17-glucuronide antiserum with selected steroids is 
listed in table 1. 
4. Discussion 
Several investigators have attempted to develop a 
radioimmunoassay method for the steroid glucuronide 
not involving prior hydrolysis [l-5]. These approaches, 
however, failed due to insufficient specificity of the 
antiserum used. The unsatisfactory results appeared to 
be ascribable to the structure of the antigens, in 
which the steroid was coupled to protein through the 
carboxyl group of the glucuronyl moiety. 
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derivable from oestradiol 17-ghtcuronide acetate-methyl 
ester in three steps, coupled to BSA using glutaraldehyde 
as a cross-linking agent [6]. It is evident from the data 
in table 1 that antiserum raised against this conjugate 
is highly specific for oestradiol 17glucuronide, 
exhibiting no significant cross-reaction with oestrogen 
ring D and A glucuronides. No cross-reactivity was 
found with free oestrogens, their sulphates and other 
steroids. 
It should be emphasised that antiserum elecited 
against the antigen in which the hapten is linked to the 
immunogenic carrier through the C-2 position remote 
from ring D, is capable of discriminating oestradiol 
17glucuronide from its closely related free and 
conjugated oestrogens. The design of similar hapten- 
carrier conjugates may be further applicable to the 
preparation of antisera specific for other steroid 
conjugates. 
Acknowledgement 
References 
[l ] Kellie, A. E., Samuel, V. K., Riley, W. J. and Robertson, 
D. M. (1972) J. Steroid Biochem. 3, 275-288. 
[2] Samarajeewa, P. and Kellie, A. E. (1975) Biochem. J. 151, 
369-376. 
[3] Niswender, G. D., Nett, T. M., Meyer, D. L. and Hagerman, 
D. D. (1975) in: Steroid Immunoassay, Proc. Fifth Tenovus 
Workshop (Cameron, E. H. D., Hillier, S. G. and Griffiths, 
K. eds) pp. 61-66, Alpha Omega Publishing, Cardiff. 
[4] Adlercreutz, H., Lehtinen, T. and Tikkanen, M. (1976) J. 
Steroid Biochem. 7, 105-107. 
[S] Soares, J. R., Zimmermann, E. and Gross, S. J. (1976) 
FEBS Letters 61, 263-266. 
[6] Avrameas, S. (1969) Immunochemistry 6,43-52. 
[7] Nambara, T., Takahashi, M., Tsuchida, Y. and Numazawa, M. 
(1974) Chem. Pharm. Bull. (Tokyo) 22,2176-2180. 
[8] Scatchard, G. (1949) Ann. NY Acad. Sci. 5 1,660-672. 
This work was supported by a grant from the 
Society for Promotion of Cancer Research, Japan. 
217 
